U.S. Pharma Stock News

If you are wondering whether Akamai Technologies is fairly priced or if the recent buzz has left it mispriced, you are in the right place for a closer look at what the current share price might be implying. Akamai's share price closed at US$105.47, with returns of 4.4% over 7 days, 11.7% over 30 days, 23.9% year to date, 34.1% over 1 year and 45.4% over 3 years, while the 5 year return stands at 7.4%. These price moves sit against an ongoing focus on Akamai's role in content delivery and...

If you have been wondering whether US Foods Holding is still reasonably priced after its recent run, this article walks through what the numbers actually say about its current value. The stock last closed at US$92.61, with returns of 0.5% over 7 days, 2.1% over 30 days, 24.1% year to date and 45.4% over the past year, while the 3 year and 5 year returns sit at 167.8% and 151.3% respectively. Recent attention on US Foods has been driven by ongoing interest in large foodservice distributors...

Recent analysis highlighted that CorVel passed a high-quality investment screen, underpinned by very large returns on invested capital and a debt-free balance sheet in its cost containment and claims management business. This focus on financial strength and operational resilience has drawn attention from investors who prioritize durable business models and conservative balance sheets. Next, we’ll examine how CorVel’s debt-free position shapes its investment narrative in light of the latest...

Merck (MRK) is back on investors’ radar after recent trading left the shares around $115.91, with short term returns mixed, while the past 3 months and year have shown stronger overall performance metrics. See our latest analysis for Merck. Short term share price returns for Merck have been soft, but a 15.56% 90 day share price return and 26.99% 1 year total shareholder return suggest momentum has recently been building for long term holders. If Merck’s moves have you reassessing healthcare,...

Cinemark Holdings (CNK) shares have been relatively steady recently, with a one-month return near flat and a gain of about 4% over the past three months, prompting investors to reassess the cinema operator’s current valuation and earnings profile. See our latest analysis for Cinemark Holdings. At a share price of US$25.53, Cinemark’s recent moves include a 9.63% 7 day share price pullback alongside an 8.50% year to date share price return and a 3 year total shareholder return above 100%. This...

If you are wondering whether Robinhood Markets at around US$76 per share is priced for perfection or still has room based on fundamentals, you are not alone. The stock has pulled back recently, with a 5.5% decline over the last 7 days and an 11.1% decline over the last 30 days. However, the 1 year return sits at 111.3% and the 3 year gain is very large at around 7x. That swing in sentiment comes as Robinhood stays in the headlines for its role as a major retail trading platform and for...

Wave Life Sciences (WVE) drew investor attention after reporting interim Phase I data for its INHBE obesity candidate WVE-007, and detailing a cash position it expects to fund multiple trials and regulatory milestones through 2026. See our latest analysis for Wave Life Sciences. The latest WVE-007 readout and funding runway arrive after a 1-year total shareholder return of about 30% and a very large 3-year total shareholder return, even as the 90-day share price return of a 19.38% decline and...

Playtika Holding (NasdaqGS:PLTK) announced that Chief Financial Officer and President Craig Abrahams will resign effective April 1, 2026. Tae Lee, who has corporate finance experience at Playtika and Meta, will become acting CFO when the change takes effect. Board Chairperson Robert Antokol will also assume the role of President, taking on an expanded leadership position. Playtika operates in the mobile gaming sector, where user engagement, live operations and content updates tend to matter...

Sunrun (RUN) is back on investors’ radar after recent trading has highlighted how volatile the stock can be, with sharp swings over the past month and past 3 months drawing fresh scrutiny. See our latest analysis for Sunrun. At a share price of US$11.97, Sunrun’s recent 30 day and year to date share price returns of 42.06% and 38.43% declines sit in contrast with a 1 year total shareholder return of 92.75%. This suggests that earlier optimism has cooled while longer term holders still sit on...

RLX Technology Inc. has reported its full-year 2025 results, with revenue of CNY 3,958.86 million and net income of CNY 921.87 million, alongside higher basic and diluted earnings per share from continuing operations compared with 2024. Over the course of its CNY 330 million share repurchase program completed in 2025, RLX bought back 12.71% of its shares, meaning recent profit growth is now spread across a meaningfully smaller share count. With full-year earnings rising and a sizeable...

Integer Holdings event overview Integer Holdings (ITGR) has drawn fresh attention after recent share price moves, with the stock down about 3% over the past month and up roughly 15% in the past 3 months. See our latest analysis for Integer Holdings. The 1-year total shareholder return decline of 29.65% contrasts with the recent 14.55% 90-day share price return. This suggests momentum has picked up after a weaker stretch for long-term holders at the latest share price of US$83.30. If Integer’s...

Fluor (NYSE:FLR) is opening a new office in Bucharest, Romania to support advanced nuclear energy projects in Eastern Europe. The office will focus on major Romanian projects, including the Doicești small modular reactor installation and the expansion of the Cernavodă nuclear power plant. This move reflects Fluor’s broader push into European nuclear infrastructure and clean energy solutions. For you as an investor, the Bucharest office highlights how Fluor is positioning its engineering and...

BridgeBio Pharma recently presented additional positive interim data from its Phase 3 FORTIFY trial of oral BBP-418 in LGMD2I/R9, showing broad efficacy across mobility, biomarker, and subgroup endpoints, along with a safety profile comparable to placebo. These results underpin BridgeBio’s plan to file for US FDA approval in the first half of 2026, positioning BBP-418 as a potential first-ever approved therapy for any form of limb-girdle muscular dystrophy and highlighting the company’s...

Merchants Bancorp recently reported quarterly results that exceeded analyst expectations for revenue, earnings per share and net interest income, highlighting continued strength in its low-risk, government-backed lending programs such as multi-family mortgage banking and mortgage warehousing. This earnings beat underscores how the bank’s focus on government-supported credit channels can support business resilience even when broader financial conditions are uncertain. Next, we will examine...

Netskope (NTSK) sets the stage with FY 2026 numbers Netskope (NTSK) has just put fresh FY 2026 figures on the table, with fourth quarter revenue at US$196.3 million and a basic EPS loss of US$0.14, alongside a full year basic EPS loss of US$3.18 on trailing twelve month revenue of US$709.0 million. Over recent quarters the company has seen revenue move from US$148.5 million in Q4 FY 2025 to US$196.3 million in Q4 FY 2026, while quarterly basic EPS has ranged from a loss of US$0.72 to a loss...

What is driving interest in U.S. Bancorp stock right now? U.S. Bancorp (USB) is back in focus after Q4 results that slightly topped revenue expectations but missed tangible book value per share estimates, alongside fresh dividend declarations and visible shifts in institutional ownership. See our latest analysis for U.S. Bancorp. The latest sell off has taken U.S. Bancorp’s share price to US$51.48, with a 1 month share price return of negative 14.98% and a year to date share price return of...

Kosmos Energy (KOS) has completed a large follow-on equity offering of 97,500,000 common shares at US$1.90, raising about US$185.25 million to repay commercial debt and other outstanding borrowings. See our latest analysis for Kosmos Energy. The follow on offering sits against a sharp rebound in Kosmos Energy’s 90 day share price return of 123.53% and year to date share price return of 155.38%. However, the 3 year total shareholder return is a 64.21% loss, suggesting recent momentum has...

DTE Energy disclosed in a recent SEC filing that President and CEO Joi Harris received an estimated US$8,457,065 in 2025 compensation, up very large from 2024, while several major institutional investors, including Capital World Investors and Capital International Inc. CA, increased their stakes in the company over the third quarter of 2025. This combination of higher leadership pay and rising institutional ownership highlights how large investors and the board are responding to DTE’s...

Unusual Machines (UMAC) is back in focus after its latest earnings report, which showed full year 2025 sales of US$11.2 million, a net loss of US$19.2 million, and a reduced basic loss per share. See our latest analysis for Unusual Machines. The stock has reacted strongly around these updates, with a 1 day share price return of 11.64% and a 30 day share price return of 75.79%. This has contributed to a very large 1 year total shareholder return of 291.34%, which suggests momentum has been...

Why Molina Healthcare Is On Investors’ Radar Today Molina Healthcare (MOH) has drawn investor attention after a period where the share price shows mixed returns, with gains over the month but weaker performance over the past 3 months and year. See our latest analysis for Molina Healthcare. The recent 18.94% 1-month share price return suggests some momentum is coming back into the stock, although the 16.40% year-to-date share price decline and 52.04% 1-year total shareholder return loss show...

Why Sunoco (SUN) is on investors’ radar today Sunoco (SUN) has attracted fresh attention after recent share price moves, with the stock down 1.5% over the past day but up in the month and past 3 months. Investors are weighing how this shorter term volatility fits with its broader performance profile. See our latest analysis for Sunoco. While the share price has seen a 1 day pullback, Sunoco’s 30 day share price return of 6.35% and 90 day gain of 16.82% suggest momentum has been building,...

If you are wondering whether LKQ's recent share price weakness has left the stock looking mispriced, this breakdown will help you weigh what you are paying against what you are getting. The shares recently closed at US$29.75, with returns of a 5.4% decline over 7 days, a 14.0% decline over 30 days, a 0.9% decline year to date and a 25.2% decline over 1 year, alongside a 40.6% decline over 3 years and a 23.2% decline over 5 years. Recent coverage around LKQ has focused on its position as a...

Sonos, Inc. (NasdaqGS:SONO) has released two new speakers, the Sonos Play and Era 100 SL. This marks the company’s first major product launch in more than a year. The products target portable and entry-level smart audio and are built to plug into the broader Sonos platform and ecosystem. The move follows criticism around stagnant revenue and limited business expansion. Sonos operates in connected home audio, where competition spans everything from premium sound systems to low cost smart...

If you are wondering whether Flutter Entertainment's share price now reflects a fair deal or an overreaction, you are not alone. This article will help you frame that question clearly. The stock has retreated to US$105.53, with returns of a 7.9% decline over the past week, a 30.4% decline over the past month, and a 51.7% decline year to date. These moves may already be reshaping how investors think about its risk and potential reward. Recent coverage of Flutter has kept attention on its...